Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage

Journal of Hepatology

Volumn 62, Issue 4, 2015, Pages 779-784

  Welsch, Christoph ^a,b   Haselow, Katrin ^a   Gouttenoire, Jérôme ^c   Schneider, Markus ^d   Morikawa, Kenichi ^c,e   Martinez, Yolanda ^a   Susser, Simone ^a   Sarrazin, Christoph ^a   Zeuzem, Stefan ^a   Antes, Iris ^d   Moradpour, Darius ^c   Lange, Christian M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

All oral therapy; Cardif; Direct acting antiviral agent; Innate immunity; RIG I signaling

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE INHIBITOR; ANTIVIRUS AGENT; DDX58 PROTEIN, HUMAN; DEAD BOX PROTEIN; NS3 PROTEIN, HEPATITIS C VIRUS; RNA HELICASE; SERINE PROTEINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; VIRUS PROTEIN; VIRUS RNA; VISA PROTEIN, HUMAN;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; LUCIFERASE ASSAY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SITE DIRECTED MUTAGENESIS; STATIC ELECTRICITY; WILD TYPE; ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS C; CULTURE TECHNIQUE; HEPACIVIRUS; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; DEAD-BOX RNA HELICASES; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; RNA HELICASES; RNA, VIRAL; SERINE ENDOPEPTIDASES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84926420971     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.11.009     Document Type: Article

References (21)

1. C.M. Lange, I.M. Jacobson, C.M. Rice, and S. Zeuzem Emerging therapies for the treatment of hepatitis C EMBO Mol Med 6 2014 4 15
2. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, and K. Agarwal ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
3. R. Bartenschlager, V. Lohmann, and F. Penin The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection Nat Rev Microbiol 11 2013 482 496
4. J.W. Schoggins, and C.M. Rice Innate immune responses to hepatitis C virus Curr Top Microbiol Immunol 369 2013 219 242
5. R. Thimme, M. Binder, and R. Bartenschlager Failure of innate and adaptive immune responses in controlling hepatitis C virus infection FEMS Microbiol Rev 36 2012 663 683
6. K. Morikawa, J. Gouttenoire, C. Hernandez, V.L. Dao Thi, H.T. Tran, and C.M. Lange Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease Hepatology 59 2014 423 433
7. K.J. Blight, A.A. Kolykhalov, and C.M. Rice Efficient initiation of HCV RNA replication in cell culture Science 290 2000 1972 1974
8. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, and U. Karey Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
9. B. Wolk, D. Sansonno, H.G. Krausslich, F. Dammacco, C.M. Rice, and H.E. Blum Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines J Virol 74 2000 2293 2304
10. V. Brass, E. Bieck, R. Montserret, B. Wolk, J.A. Hellings, and H.E. Blum An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A J Biol Chem 277 2002 8130 8139
11. D. Moradpour, P. Kary, C.M. Rice, and H.E. Blum Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins Hepatology 28 1998 192 201
12. E. Meylan, J. Curran, K. Hofmann, D. Moradpour, M. Binder, and R. Bartenschlager Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus Nature 437 2005 1167 1172
13. B. Hess, D. Kutzner, D. van Der Spoel, and E. Lindahl GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation J Chem Theory Comput 4 2008 1549
14. C. Oostenbrink, A. Villa, A.E. Mark, and W.F. van Gunsteren A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6 J Comput Chem 25 2004 1656 1676
15. K.P. Romano, J.M. Laine, L.M. Deveau, H. Cao, F. Massi, and C.A. Schiffer Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease J Virol 85 2011 6106 6116
16. C. Hartmann, I. Antes, and T. Lengauer IRECS: a new algorithm for the selection of most probable ensembles of side-chain conformations in protein models Protein Sci 16 2007 1294 1307
17. H.J. Berendsen, J.P.M. Postma, W.F. van Gunsteren, A. Di Nola, and J.R. Haak Molecular dynamics with coupling to an external bath J Chem Phys 81 1984 3684
18. B. Hess, H. Bekker, H.J. Berendsen, and J.G.E.M. Fraaije LINCS: a linear constraint solver for molecular simulations J Comput Chem 18 1997 1463
19. W. Humphrey, A. Dalke, and K. Schulten VMD: visual molecular dynamics J Mol Graph 14 1996 27 38
20. K.P. Romano, A. Ali, C. Aydin, D. Soumana, A. Ozen, and L.M. Deveau The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors PLoS Pathog 8 2012 e1002832
21. C. Welsch, T. Shimakami, C. Hartmann, Y. Yang, F.S. Domingues, and T. Lengauer Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease Gastroenterology 142 2012 654 663